Charakterystyka klonu MRSA o obnizonej wrazliwosci na wankomycyne

• Autorzy: Mlynarczyk G. , Mlynarczyk A. , Luczak M. , Jeljaszewicz J.
• Języki publikacji: PL

Abstrakty

PL

Badano poziom wrażliwości na wankomycynę szczepów Staphylococcus aureus. Wykazano, że szczepy o podwyższonym MIC występowały wyłącznie w grupie gronkowców opornych na metycylinę oraz charakteryzujących się opornością na wiele innych antybiotyków. W celu oceny czy wszystkie te szczepy stanowiły jeden klon rozprzestrzeniony na kilku oddziałach szpitalnych przeprowadzono analizę epidemiologiczną.

EN

The MIC of vancomycin was determined for all S. aureus strains isolated during 1997 in one hospital. MIC values for most isolates were in the range of 0,5 — 2 mg/l. In 18 strains, MIC was = 6mg/L. All these strains were MRSA. Recently described VISA strains possessed MIC values for vancomycin equal or higher than 8 mg/l and such strains were not detected in the investigated group. Although strains with MIC = 6 mg/l are not VISA, but they are candidate for reduced vancomycin susceptibility, e.g. during therapy in compromised patients. Analysis of DNA of these strains by pulsed-field gel electrophoresis (PFGE) revealed that 15 of them shared a significant similarity, allowing to place them in the same group. The comparison data of phage patterns as well as antibiotic resistance patterns strongly suggest that all these strains were derivatives of a single clone.

Słowa kluczowe

PL

infekcja bakteryjna; szczepy bakteryjne; antybiotyki; wankomycyna; leczenie; analiza epidemiologiczna; wrazliwosc na wankomycyne; opornosc na metycyline; Staphylococcus aureus

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2000
• Tom: 52
• Numer: 3
• Opis fizyczny: s.223-228,fot.,tab.,bibliogr.

Twórcy

autor

Mlynarczyk G.

• Akademia Medyczna, 02-004 Warszawa, ul.Chalubinskiego 5

autor

Mlynarczyk A.

autor

Luczak M.

autor

Jeljaszewicz J.

Bibliografia

• 1. Arthur M, Departieu F, Cabanié L i inni. Requirement of the VanY and VanX D,D-peptidases for glycopeptide resistance in enterococci. Mol Microbiol 1998; 30: 819-30.
• 2. Boyle-Vavra S, De Jonge BLM, Ebert CC, Daum RS. Cloning of the Staphylococcus aureus ddh gene encoding NAD+-dependent D-lactate dehydrogenase and insertional inactivation in a glycopeptide-resistant isolate. J Bacteriol 1997; 179: 6756-63.
• 3. Fines M, Perichon B, Reynolds P i inni. VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405. Antimicrob Agents Chemother 1999; 43: 2161-64.
• 4. Hiramatsu K, Hanaki H, Ini T i inni. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.
• 5. Hiramatsu K, Aritaka N, Hanaki H i inni. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-73.
• 6. Jeljaszewicz J, Młynarczyk G, Młynarczyk A. Present and future problems of resistance in Gram-positive cocci. Infection 1998; 26: 1-6.
• 7. Marshal CG, Lessard AD, Park IS, Wright GD. Glycopeptide antibiotic resistance genes in glycopeptide-producing organisms. Antimicrob Agents Chemother 1998; 42: 2215-20.
• 8. Milewski WM, Boyle-Vavra S, Moreira B i inni. Overproduction of a 37 kilodalton cytoplasmatic protein homologous to NAD+-linked D-lactate dehydrogenase associated with vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1996; 40: 166-72.
• 9. Młynarczyk G, Młynarczyk A, Żabicka D, Jeljaszewicz J. Lysogenic conversion as a factor influencing the vancomycin tolerance phenomenon in Staphylococcus aureus. J Antimicrob Chemother 1997; 39: 136-37.
• 10. Młynarczyk G, Rosdahl VT, Skov R, Młynarczyk A. Epidemiology of methicillin resistant Staphylococcus aureus in a Warsaw hospital. J Hosp Infect 1996; 34: 151-60.
• 11. National Committee for Clinical Laboratory Standards. Performance Standards for antimicrobial susceptibility testing. National Committee for Clinical Laboratory Standards, Villanova, Pa, 1993.
• 12. Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 1989; 8: 943-50.
• 13. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340: 517-23.
• 14. Sieradzki K, Tomasz K. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997; 179: 2557-66.
• 15. Sieradzki K, Villari P, Tomasz A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 1998; 42: 100-107.
• 16. Smith TL, Pearson ML, Wilcox KR i inni. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340: 439-501.
• 17. Tenover FC, Lancaster MV, Hill BC i inni. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36 1020-27.
• 18. Woodford N, Johnson AP, D Morrison D, Speller DCE. Current perspectives on glycopeptide resistance. Clin Microbiol Rev 1995; 8: 585-615.